Use of Apixaban and Post TAVR Valve Thrombosis

TAVR can be associated to early valve thrombosis, characterized by thrombi formation near or attached to the prosthetic valve, with or without valve dysfunction. This dysfunction is associated with increased leaf thickening and reduced leaflet motion, as well as reduced orifice area or increased transvalvular gradient. Triggered multislice CT allows dynamic valve assessment and thrombosis<a href="https://solaci.org/en/2024/01/25/use-of-apixaban-and-post-tavr-valve-thrombosis/" title="Read more" >...</a>

Optical Coherent Tomography: OCT: Thrombosis

Por Dr. Marcelo Freitas.

Resultados a 2 años de los stents liberadores de Zotarolimus vs stents libres de polímero liberadores de Biolimus. ¿Son seguros en pacientes con alto riesgo de sangrado?

Stent Thrombosis: Clinical Characteristics and Event Predictors in a Contemporary Cohort

Stent thrombosis (ST) is a serious complication of coronary PCI. However, its incidence across registries is low. It has been classified according to onset into acute (less than 24 hrs.), subacute (between 24 and 30 days), late (between 30 and 365 days) and very late (later than 365 days).  The estimated incidence of ST is<a href="https://solaci.org/en/2022/10/27/stent-thrombosis-clinical-characteristics-and-event-predictors-in-a-contemporary-cohort/" title="Read more" >...</a>

Apixaban and Valve Thrombosis after TAVR

TAVR has been associated with early valve thrombosis, characterized by thrombus formation in the prosthetic valve with or without valve dysfunction. This dysfunction is related to leaflet thickening and reduced motion, reduced effective orifice area, or increased transvalvular gradient. A multidetector CT scan allows the dynamic assessment of valves and ruling out fibrosis vs. thrombosis. <a href="https://solaci.org/en/2022/09/14/apixaban-and-valve-thrombosis-after-tavr/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet thrombosis compared with the standard of care. These data come from the computerized tomography (CT) scan sub-study from ATLANTIS, presented during the scientific sessions of the American College of Cardiology (ACC) 2021 Congress. In patients with no prior<a href="https://solaci.org/en/2021/05/19/acc-2021-atlantis-4d-ct-apixaban-and-sub-clinical-thrombosis-after-tavr/" title="Read more" >...</a>

Recomendaciones de la ACC con el nuevo coronavirus

Diagnosis and Treatment of Vaccine-Induced Thrombosis

Cerebral venous sinus thrombosis is an extremely rare manifestation of cerebrovascular disease.  In the last few days, this pathology has sadly gained fame due to its association with two vector-based vaccines against SARR COV19.  These are Ad26.COV2.S (Johnson & Johnson) and ChAdOx1 nCoV-19 (AstraZeneca). There have not been any reports of thrombosis or thrombocytopenia from<a href="https://solaci.org/en/2021/05/07/diagnosis-and-treatment-of-vaccine-induced-thrombosis/" title="Read more" >...</a>

Es posible esterilizar las máscaras N95 y los barbijos quirúrgicos

Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports

This is one of the first papers documenting rare thrombotic effects related to the ChAdOx1 nCoV-19 vaccine in Austria and Germany. These effects may be a type of thrombocytopenia after inoculation with the vaccine developed by Oxford University and AstraZeneca. This paper, published in the prestigious New England Journal of Medicine (NEJM), has received plenty<a href="https://solaci.org/en/2021/04/21/thrombocytopenia-and-thrombosis-may-be-linked-to-astrazeneca-vaccine-analysis-reports/" title="Read more" >...</a>

Vasculitis, Thrombosis and Angiogenesis: Covid-19´s Unique Patters

In this small, yet interesting series, we observe angiogenesis could differentiate pulmonary physiopathology by Covid-19 vs. from viral infections of similar severity (such as influenza). Being quite small, we can hardly consider it universal, or whether it could have clinical impact. Meanwhile, we keep learning about the new virus.  Progressive respiratory failure is the main<a href="https://solaci.org/en/2020/07/22/vasculitis-thrombosis-and-angiogenesis-covid-19s-unique-patters/" title="Read more" >...</a>

Thrombosis and Thromboembolism Associated with COVID-19

Coronavirus disease 2019 (COVID-19) is a viral respiratory illness that can cause a severe acute respiratory syndrome (SARS-CoV-2), predisposing patients to thrombosis (both in veins and arteries) due to excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for different indications may now become infected with COVID-19, which can<a href="https://solaci.org/en/2020/05/13/thrombosis-and-thromboembolism-associated-with-covid-19/" title="Read more" >...</a>

AHA 2019 | GALILEO-4D: rivaroxabán y prevención de engrosamiento y trombosis de las valvas post TAVI

AHA 2019 | GALILEO-4D: Rivaroxaban in the Prevention of Post TAVR Valve Thickening and Thrombosis

This sub study of the GALILEO specifically looked at valve thickening and reduced leaflet motion after TAVR documented with 4D CT. Whether anticoagulation with rivaroxaban might reduce or prevent this phenomenon remained unanswered. Patients receiving the same anticoagulation scheme than the general study’s (rivaroxaban + aspirin vs. aspirin + clopidogrel) were assessed by 4D CT<a href="https://solaci.org/en/2019/11/20/aha-2019-galileo-4d-rivaroxaban-in-the-prevention-of-post-tavr-valve-thickening-and-thrombosis/" title="Read more" >...</a>